Table 1 Characteristics of patients with advanced prostate cancer in the training set
Variables | Total (n = 16,803) | Alive (n = 15,299) | Dead (n = 1504) | Statistics | P |
|---|---|---|---|---|---|
Age (years), mean ± SD | 63.66 ± 7.80 | 63.19 ± 7.38 | 68.45 ± 10.07 | t=-19.75 | < 0.001 |
Race, n (%) | χ2 = 21.517 | < 0.001 | |||
Blacks | 2222 (13.22) | 1977 (12.92) | 245 (16.29) | ||
Other (American Indian/AK Native, Asia | 1065 (6.34) | 972 (6.35) | 93 (6.18) | ||
Unknown | 166 (0.99) | 162 (1.06) | 4 (0.27) | ||
Whites | 13,350 (79.45) | 12,188 (79.67) | 1162 (77.26) | ||
Marital status, n (%) | χ2 = 133.345 | < 0.001 | |||
Divorced | 1246 (7.42) | 1093 (7.14) | 153 (10.17) | ||
Married | 11,986 (71.33) | 11,077 (72.40) | 909 (60.44) | ||
Separated | 142 (0.85) | 120 (0.78) | 22 (1.46) | ||
Single | 1937 (11.53) | 1716 (11.22) | 221 (14.69) | ||
Unknown | 997 (5.93) | 902 (5.90) | 95 (6.32) | ||
Unmarried or Domestic Partner | 49 (0.29) | 43 (0.28) | 6 (0.40) | ||
Widowed | 446 (2.65) | 348 (2.27) | 98 (6.52) | ||
Insurance status, n (%) | χ2 = 106.765 | < 0.001 | |||
Any Medicaid | 1006 (5.99) | 837 (5.47) | 169 (11.24) | ||
Insurance status unknown | 358 (2.13) | 318 (2.08) | 40 (2.66) | ||
Insured | 12,589 (74.92) | 11,597 (75.80) | 992 (65.96) | ||
Insured/No specifics | 2543 (15.13) | 2268 (14.82) | 275 (18.28) | ||
Uninsured | 307 (1.83) | 279 (1.82) | 28 (1.86) | ||
Histology, n (%) | χ2 = 43.039 | < 0.001 | |||
adenocarcinoma | 205 (1.22) | 160 (1.05) | 45 (2.99) | ||
Non-adenocarcinoma | 16,598 (98.78) | 15,139 (98.95) | 1459 (97.01) | ||
Stage, n (%) | χ2 = 1722.360 | < 0.001 | |||
Distant site/node involved | 1143 (6.80) | 537 (3.51) | 606 (40.29) | ||
Localized only | 12 (0.07) | 12 (0.08) | 0 (0.00) | ||
Regional by direct extension and lymph nodes | 1868 (11.12) | 1689 (11.04) | 179 (11.90) | ||
Regional by direct extension only | 13,778 (82.00) | 13,059 (85.36) | 719 (47.81) | ||
Regional by direct extension only | 2 (0.01) | 2 (0.01) | 0 (0.00) | ||
Tumor size (mm), M (Q1, Q3) | 114.00 (33.00, 114.00) | 114.00 (31.00, 114.00) | 114.00 (114.00, 114.00) | Z = 14.757 | < 0.001 |
Radiotherapy, n (%) | χ2 = 8.408 | 0.004 | |||
No/Unknown | 14,178 (84.38) | 12,870 (84.12) | 1308 (86.97) | ||
Yes | 2625 (15.62) | 2429 (15.88) | 196 (13.03) | ||
Surgery, n (%) | χ2 = 1588.610 | < 0.001 | |||
No/Unknown | 2345 (13.96) | 1624 (10.62) | 721 (47.94) | ||
Surgery performed | 14,458 (86.04) | 13,675 (89.38) | 783 (52.06) | ||
Chemotherapy, n (%) | χ2 = 214.788 | < 0.001 | |||
No/unknown | 16,530 (98.38) | 15,119 (98.82) | 1411 (93.82) | ||
Yes | 273 (1.62) | 180 (1.18) | 93 (6.18) | ||
T stage, n (%) | χ2 = 1067.498 | < 0.001 | |||
T3a | 9258 (55.10) | 8837 (57.76) | 421 (27.99) | ||
T3b | 4976 (29.61) | 4544 (29.70) | 432 (28.72) | ||
T4 | 2569 (15.29) | 1918 (12.54) | 651 (43.28) | ||
N stage, n (%) | χ2 = 460.789 | < 0.001 | |||
N0 | 14,343 (85.36) | 13,340 (87.20) | 1003 (66.69) | ||
N1 | 2460 (14.64) | 1959 (12.80) | 501 (33.31) | ||
M stage, n (%) | χ2 = 2881.475 | < 0.001 | |||
M0 | 15,709 (93.49) | 14,793 (96.69) | 916 (60.90) | ||
M1 | 1094 (6.51) | 506 (3.31) | 588 (39.10) | ||
AJCC 8th, n (%) | χ2 = 3090.351 | < 0.001 | |||
IIIB | 13,307 (79.19) | 12,686 (82.92) | 621 (41.29) | ||
IIIC | 520 (3.09) | 410 (2.68) | 110 (7.31) | ||
IVA | 1882 (11.20) | 1697 (11.09) | 185 (12.30) | ||
IVB | 1094 (6.51) | 506 (3.31) | 588 (39.10) | ||
PSA (mg/ml), M (Q1, Q3) | 0.09 (0.06, 0.18) | 0.08 (0.05, 0.16) | 0.22 (0.08, 0.98) | Z = 24.425 | < 0.001 |
Primary Gleason pattern scores, mean ± SD | 3.63 ± 0.61 | 3.58 ± 0.59 | 4.07 ± 0.66 | t=-27.63 | < 0.001 |
Secondary Gleason pattern scores, mean ± SD | 3.84 ± 0.70 | 3.80 ± 0.68 | 4.21 ± 0.73 | t=-21.29 | < 0.001 |
Survival months, M (Q1, Q3) | 42.00 (23.00, 63.00) | 44.00 (25.00, 64.00) | 26.00 (14.00, 42.00) | Z=-25.322 | < 0.001 |